Delving into the Latest Updates on Paclitaxel with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

EmPAC, LDE-paclitaxel, NanoPac

+ [78]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders+ [10]

Active Indication

Metastatic HER2-Negative Breast CarcinomaRecurrent HER2-Negative Breast CarcinomaAdvanced gastric carcinoma+ [172]

Inactive Indication

Acidemia, IsovalericAcinar Cell CarcinomaAcute Lymphoblastic Leukemia+ [222]

Originator Organization

National Institutes of Health

Active Organization

Alliance Foundation Trials LLC

NRG Oncology

Sinphar Pharmaceutical Co. Ltd.

+ [54]

Inactive Organization

Hoffmann-La Roche, Inc.

University of Washington

Pfizer Inc.

+ [54]

License Organization

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Shenyang Sunshine Pharmaceuticals Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

+ [26]

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1992),

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving futibatinib with paclitaxel and ramucirumab may be safe and tolerable in treating patients with locally advanced or unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma.

Start Date09 Sep 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07346196

/ Not yet recruitingPhase 2IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

Start Date07 Feb 2027

Sponsor / Collaborator

The University of Chicago

NCT07753824

/ Not yet recruitingPhase 2

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).

Start Date16 Jan 2027

Sponsor / Collaborator

M.D. Anderson International España SA

[+2]

100 Clinical Results associated with Paclitaxel

Login to view more data

100 Translational Medicine associated with Paclitaxel

Login to view more data

100 Patents (Medical) associated with Paclitaxel

Login to view more data

47,579

Literatures (Medical) associated with Paclitaxel

01 Feb 2027·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A leakage-controlled multiscale contextual involution-inception framework for spectral-spatial classification of neonatal hyperspectral images

Article

Author: Ceylan, Murat ; Cihan, Mücahit

Early and reliable assessment of neonatal conditions is important in neonatal intensive care units, where non-invasive imaging approaches may provide complementary information for clinical evaluation. Hyperspectral imaging provides a non-invasive means of capturing spatially resolved spectral information from neonatal tissue; however, its high dimensionality and the limited availability of clinical samples make robust model development challenging. This study proposes the Multiscale Contextual Involution-Inception Network (MC-I²Net), a leakage-controlled framework for neonatal HSI classification. The model combines spatially adaptive involution operators, Inception-based multiscale feature extraction, and contextual feature fusion to learn compact and discriminative spectral-spatial representations. A balanced six-class neonatal hyperspectral imaging dataset containing 240 samples was evaluated, including coarctation of the aorta, intracranial hemorrhage, necrotizing enterocolitis, pneumothorax, respiratory distress syndrome, and healthy control groups. Fixed signal-conditioning operations were applied using predefined processing rules, whereas PCA was treated as a data-adaptive transformation. PCA was fitted exclusively on each training fold, and the learned transformation was subsequently applied to the corresponding held-out test fold. All models were assessed using the same 5-fold cross-validation protocol repeated 10 times. MC-I²Net achieved an overall accuracy of 94.38 ± 4.60% and a Macro-F1 score of 94.35 ± 4.57%, with only small numerical differences in OA relative to MC-3DCNN, ViT-HSI, and Swin-HSI. The model used fewer trainable parameters than MC-3DCNN, ViT-HSI, and Swin-HSI and substantially fewer FLOPs than MC-3DCNN, supporting a favorable performance-complexity profile rather than a large predictive-performance margin. An additional anatomically controlled analysis restricted to PTX and RDS samples acquired from the same thoracic region retained an OA of 95.75 ± 6.49% and a Macro-F1 score of 95.66 ± 6.68%. Sequential nested cross-validation, with PCA dimensionality and involution hyperparameters selected using training data only, yielded a pooled outer out-of-fold OA of 95.00% and a Macro-F1 score of 94.98%. Ablation, sensitivity, calibration, nested-validation, runtime, and saliency analyses provided complementary evidence regarding architectural behavior, robustness, computational characteristics, and preliminary explainability. Overall, these findings support MC-I²Net as a proof-of-concept framework for neonatal HSI classification and provide a methodological basis for future prospective, multicenter, and cross-device evaluation.

01 Feb 2027·BIOMATERIALS

Paving the way for immunotherapy: Simvastatin-primed dual-targeting NPTAC overcomes immune resistance in hepatocellular carcinoma

Article

Author: Chen, Chen ; Yin, Dengke ; Li, Yunlong ; Song, Zhengwei ; Huang, Danni ; Yang, Wenshuo ; Liu, Kang ; Sun, Quanwei ; Yang, Ye ; Shen, Wei ; Niu, Wenjing ; Yu, Qiongliu

Immune checkpoint blockade (ICB)-based regimens, tyrosine kinase inhibitors, and transcatheter arterial chemoembolization (TACE) are major clinical options for unresectable hepatocellular carcinoma (HCC), yet their efficacy remains limited by poor tumor targeting, low response rates, insufficient immune activation, and systemic toxicity. To address these challenges, we establish a "Pave the Way Strategy" combining simvastatin (SIM) with a dual-targeted nanoparticle-mediated targeting chimera (Hs/αPD-L1-NPTAC). Oral SIM acts as a dual-function paving agent, it upregulates hepatic low-density lipoprotein receptor (LDLR) expression to enhance nanoparticle delivery, and depletes tumor cell membrane cholesterol to increase rigidity, boosting dendritic cell phagocytosis and antigen presentation. The LDLR/PD-L1 dual-targeted Hs/αPD-L1-NPTAC enables precise HCC targeting and synchronous intracellular functions. It releases paclitaxel (PTX), promotes intracellular downregulation of PD-L1 and LDLR through endolysosomal trafficking, and cooperates with SIM to establish dual metabolic intervention by simultaneously suppressing cholesterol synthesis and limiting exogenous cholesterol uptake. In immunocompetent orthotopic HCC models, this strategy potently inhibits tumor growth and lung metastasis, prolongs survival, enhances CD8⁺ cytotoxicity T cell, and remodels the immunosuppressive tumor microenvironment. This paradigm provides a promising approach to overcome ICB resistance and enable precision immunotherapy for HCC.

01 Feb 2027·BIOMATERIALS

Natural phenolic acid-based self-assembly promotes anti-tumor immune amplification by ATP-ADO axis regulation and its spiky structure

Article

Author: Zhao, Xiaomin ; Ruan, Xin ; Zhou, Guoliang ; Wang, Xin ; Yue, Zongxin ; Cao, Yuqi ; Deng, Dawei ; Liu, Xinhe ; Hu, Jia

The integration of bioactive micro-nano drug carrier components with rational design of morphological structures is poised to address the therapeutic challenge in anti-tumor immunotherapy focusing on immunogenic cell death (ICD). In this article, based on ATP-adenosine (ADO) axis regulation induced by ellagic acid (EA), the spiky self-assembly (EZ) was tailored with EA and Zn²⁺, and next engineered to construct ATP and pH dual-responsive EZ@MTPP for anti-tumor immune amplification. Following intratumoral injection, the spiky structure of EZ@MTPP enabled efficient local retention, then the ATP-sensitive spines of EZ slowly discharged EA and Zn²⁺ while scavenging ATP. EA silenced the ATP-ADO pathway, lowering immunosuppressive ADO and PD-L1 levels, and Zn²⁺ activated the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) stimulator of interferon genes (STING) signaling pathway cascade and downstream immunity. Concomitantly, acidification of the TME triggered detachment of microwave-induced tumor-derived microparticles loaded with paclitaxel (MTPP) from EZ, which were acquired by neighboring tumor cells to release paclitaxel (PTX) to elicit apoptosis and robust ICD. After coupling the spiky EA-based self-assembly with PTX-loaded MTPP, EZ@MTPP MPs eradicated tumor cells, relieved ADO-mediated immunosuppression and amplified ICD-driven immunity by components and morphological structures co-facilitation, offering an innovative paradigm for metabolism-focused cancer immunotherapy.

1,552

News (Medical) associated with Paclitaxel

26 Oct 2026

·www.prnewswire.com

Mount Sinai Medical Center Physician Leads Global Phase 3 Trial Showing Chemotherapy-Free Treatment Improves Outcomes for Women with dMMR Endometrial Cancer

.release-content span.prnews_span{font-size:8pt;font-family:"Arial";color:black}.release-content a.prnews_a{color:blue}.release-content li.prnews_li{font-size:8pt;font-family:"Arial";color:black}.release-content p.prnews_p{font-size:0.62em;font-family:"Arial";color:black;margin:0in} KEYNOTE-C93/GOG-3064/ENGOT-en15 results presented in the ESMO 2026 Presidential Symposium and published simultaneously in The Lancet MIAMI BEACH, Fla., Oct. 26, 2026 /PRNewswire/ -- Women with advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who were treated with immunotherapy alone lived longer without their cancer progressing than women treated with chemotherapy, according to results of the global Phase 3 KEYNOTE-C93/GOG-3064/ENGOT-en15 trial presented today at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The trial was led by Brian Slomovitz, MD, Director of Gynecologic Oncology and Deputy Director of the Braman Comprehensive Cancer Center at Mount Sinai Medical Center, who served as global principal investigator on behalf of the GOG Foundation. The findings were published simultaneously in The Lancet. The randomized trial enrolled 299 patients and compared pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, with carboplatin and paclitaxel chemotherapy as first-line treatment, the first therapy patients receive for advanced or recurrent disease. Pembrolizumab reduced the risk of disease progression or death by 43% compared with chemotherapy (hazard ratio 0.57). Overall survival data are still maturing, and follow-up continues. Patients treated with pembrolizumab also reported improved quality of life, with no new safety signals. Women treated at the Braman Comprehensive Cancer Center were among the trial's participants. Endometrial cancer is the most common gynecologic cancer in the United States and one of the few cancers with rising incidence and mortality, according to the American Cancer Society. dMMR tumors make up about 30% of endometrial cancers and are the subtype most responsive to immunotherapy. Pembrolizumab is already part of an established frontline treatment regimen with platinum doublet chemotherapy for patients with primary advanced or recurrent endometrial cancer regardless of mismatch repair status. KEYNOTE-C93 asked whether, for women with dMMR tumors, chemotherapy could be removed entirely. "These results highlight the potential of a chemotherapy-free approach for certain patients with dMMR advanced or recurrent endometrial cancer, with pembrolizumab monotherapy demonstrating a clinically meaningful benefit in progression-free survival along with a favorable quality of life compared to chemotherapy," said Dr. Slomovitz. "After years of platinum-based chemotherapy serving as the frontline standard, these findings could help provide an additional treatment option beyond carboplatin plus paclitaxel in combination with KEYTRUDA for these patients." Dr. Slomovitz serves on the Board of Directors of the GOG Foundation and is Uterine Cancer Lead for GOG Partners. He has served as national or global principal investigator on multiple GOG Partners, National Cancer Institute and Alliance Foundation trials. KEYNOTE-C93 was one of 12 studies selected from across the congress for presentation in the ESMO 2026 Presidential Symposia. "When oncologists from around the world gathered to hear what's next in women's cancer care, they heard it from one of our own," said Gino R. Santorio, President and Chief Executive Officer of Mount Sinai Medical Center. "Dr. Slomovitz's leadership means the women in our community have access to the research shaping cancer care everywhere, close to home." Dr. Slomovitz is available for interviews in Madrid and upon his return. For more information, please visit . KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About Keynote C93 (GOG-3064/ENGOT-en15) KEYNOTE-C93 (GOG-3064/ENGOT-en15) is a global, randomized Phase 3 trial sponsored by Merck comparing pembrolizumab with chemotherapy in women with advanced or recurrent dMMR endometrial cancer. The results were published in The Lancet. About Mount Sinai Medical Center Founded in 1949, Mount Sinai Medical Center is the largest independent, private, not-for-profit teaching hospital in South Florida. Mount Sinai's mission is to provide quality health care to a diverse community enhanced through teaching, research, charity care, and financial responsibility. Mount Sinai's Centers of Excellence combine technology, research, and academics to provide innovative and comprehensive care in cardiology, neuroscience, oncology, urology, and orthopedics. One of the original statutory teaching hospitals in the state of Florida, Mount Sinai is the hospital of choice for those who seek the level of expertise and care that only a teaching hospital can offer. Mount Sinai currently offers ten convenient locations in Miami-Dade County, including four emergency centers, and five specialty care offices in Monroe County. SOURCE Mount Sinai Medical Center

Phase 3Clinical ResultImmunotherapy

26 Oct 2026

·firstwordpharma.com

ESMO26: Merck & Co. details Keytruda's chemo-sparing offering in endometrial cancer

Merck & Co.'s Keytruda (pembrolizumab) led to a statistically significant and clinically meaningful 29.8-month improvement in progression-free survival (PFS) over standard platinum-doublet chemotherapy in certain patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. The findings come from the Phase III KEYNOTE-C93 study, which were detailed Monday at the European Society for Medical Oncology (ESMO) congress.Investigators, headed up by Brian Slomovitz, said the results — first top-lined in July — suggest that Merck's PD-1 inhibitor could offer "a clinically relevant, chemotherapy-free, first-line treatment option" for patients with advanced or recurrent endometrial cancer, broadening treatment beyond regimens combining chemotherapy with immunotherapy.KEYNOTE-C93 randomised 299 patients with dMMR advanced or recurrent endometrial cancer to receive first-line treatment with Keytruda or carboplatin plus paclitaxel. The trial's dual primary endpoints are PFS and overall survival (OS), with a key secondary goal of overall response rate.Results presented at ESMO showed that median PFS in the Keytruda arm was 38.2 months, compared with 8.4 months for carboplatin plus paclitaxel, representing a 43% reduction in the risk of disease progression or death. The 36-month PFS rate for Merck's therapy was 52.8%, versus 30% in the chemotherapy group.While OS also "numerically favoured" Keytruda over carboplatin plus paclitaxel, the difference did not meet the prespecified criterion for statistical significance. The 36-month OS rate for Keytruda was 70.7%, compared with 62% in the chemotherapy arm.Investigators noted that 85.2% of patients with progressive disease in the carboplatin plus paclitaxel arm subsequently received Keytruda as crossover therapy or another PD-1/PD-L1 inhibitor off study, which may have skewed the survival results. In analyses that adjusted for this, a greater OS benefit was seen for Keytruda over the chemotherapy combination, with HRs of between 0.55 and 0.66.In terms of safety, grade ≥3 treatment-related adverse events occurred in 18.1% of patients in the Keytruda arm, versus 50.7% for carboplatin plus paclitaxel, with the most common being anaemia at rates of 2% and 18.1%, respectively.

Clinical ResultPhase 3

26 Oct 2026

·firstwordpharma.com

'Modest' benefit scuppers BioNTech's breast cancer ambitions for trastuzumab pamirtecan

BioNTech and DualityBiologics said Monday that a Phase III study of trastuzumab pamirtecan (BNT323/DB-1303) in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy met its primary endpoint of progression-free survival (PFS). However, the overall results from the DYNASTY-Breast02 trial suggest that the HER2-targeting antibody-drug conjugate (ADC) will not be progressing in this setting.While the companies noted that trastuzumab pamirtecan demonstrated a statistically significant improvement in PFS over investigator's choice of chemotherapy, they described the benefit as "modest." They also said that there was a higher rate of interstitial lung disease (ILD) than seen in prior studies of trastuzumab pamirtecan — although most cases were grade 1 and 2 — as well as "severe and fatal events…in a small proportion of patients."The global trial enrolled patients with HR+/HER2-low metastatic breast cancer whose disease has progressed on at least two lines of prior hormone therapy or within six months of first line hormone therapy plus CDK 4/6 inhibitor in the metastatic setting. A total of 541 participants with HER2-low expression were randomised to receive either trastuzumab pamirtecan or investigator's choice of single-agent chemotherapy, comprising capecitabine, paclitaxel or nab-paclitaxel. Along with the primary endpoint of PFS, DYNASTY-Breast02 is measuring overall survival (OS) as a secondary goal. BioNTech and DualityBio said Monday that data for OS were not yet mature at this interim analysis.Given the outcome, the companies concluded that trastuzumab pamirtecan's "potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape." The partners plan to review the data before determining next steps.AstraZeneca and Daiichi Sankyo's HER2-targeting ADC Enhertu (trastuzumab deruxtecan) is authorised in both the US and EU for the treatment of adults with unresectable or metastatic HR+, HER2-low or HER2-ultralow breast cancer that has progressed on one or more endocrine therapies in the metastatic setting. The approvals are based on the Phase III DESTINY-Breast06 study, in which patients with HER2-low tumours had a 36% lower chance of their cancer growing or spreading compared with chemotherapy.Outside of DYNASTY-Breast02, BioNTech and DualityBio are investigating trastuzumab pamirtecan in the Phase III Fern-EC-01 study for previously-treated patients with HER2-expressing advanced recurrent endometrial cancer.

Phase 3Clinical ResultDrug ApprovalADC

100 Deals associated with Paclitaxel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00491	Paclitaxel	L01CD01	DB01229

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Metastatic HER2-Negative Breast Carcinoma	China	DAE HWA PHARM Co., Ltd.	29 Sep 2026
Recurrent HER2-Negative Breast Carcinoma	China	DAE HWA PHARM Co., Ltd.	29 Sep 2026
Advanced gastric carcinoma	China	DAE HWA PHARM Co., Ltd.	19 Sep 2024
Advanced gastric carcinoma	China	Haihe Biopharma Co., Ltd.	19 Sep 2024
Pancreatic adenocarcinoma metastatic	European Union	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Iceland	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Liechtenstein	Accord Healthcare SL	05 Jan 2024
Pancreatic adenocarcinoma metastatic	Norway	Accord Healthcare SL	05 Jan 2024
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	European Union	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Iceland	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-sensitive epithelial ovarian cancer	Norway	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	European Union	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Iceland	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Liechtenstein	Inceptua SA	20 Nov 2018
Platinum-Sensitive Fallopian Tube Carcinoma	Norway	Inceptua SA	20 Nov 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	NDA/BLA	European Union	Accord Healthcare SL	09 Nov 2023
Metastatic Pancreatic Cancer	Phase 3	China	Shanghai Yizhong Pharmaceutical Co., Ltd.	21 Jan 2025
High grade glioma	Phase 3	China	Zhejiang University	01 Apr 2024
Human epidermal growth factor 2 negative carcinoma of breast	Phase 3	China	Shanghai Yizhong Pharmaceutical Co., Ltd.	25 Sep 2023
Cutaneous Squamous Cell Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Hypopharyngeal Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of head and neck metastatic	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of the hypopharynx	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous Cell Carcinoma of the Larynx	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023
Squamous cell carcinoma of the oral cavity	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	08 Jun 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05002127 (ASPEN-06, Pubmed \| Nat Med)	Phase 2/3	HER2-positive gastric cancer HER2-positive	127	Evorpacept plus Trastuzumab, Ramucirumab, and Paclitaxel	kbjhxqthgb(ervarkafgm) = auhwtimvgp yxybqeaoma (ytarzufyyb ) View more	Positive	24 Sep 2026
NCT05002127 (ASPEN-06, Pubmed \| Nat Med)	Phase 2/3	HER2-positive gastric cancer HER2-positive	127	Trastuzumab, Ramucirumab, and Paclitaxel	kbjhxqthgb(ervarkafgm) = tbtdpeeero yxybqeaoma (ytarzufyyb ) View more	Positive	24 Sep 2026
CSCO2026	Not Applicable	Nonseminomatous Germ Cell Tumor	64	High Dose Chemotherapy (HDCT) + Peripheral Blood Stem Cell Transplantation (PBSCT)	ttxvrsjosy(odovwygvbw) = skxbdqvlax pxhwnqcdtg (hxowbyfubu ) View more	Positive	11 Sep 2026
NCT02905591 (XACT-LUNG, CTgov)	Phase 2	Non-Small Cell Lung Cancer	43	Radiation therapy+Ascorbic Acid+Carboplatin+Paclitaxel	qddjxjdnpq = nbmhcknbuh nrplbrylqy (nbrcfhgjez, ajxynditby - qxhfizmzix) View more	-	31 Jul 2026
NCT04776447 (APOLLO \| APOLO, CTgov)	Phase 2	Resectable Lung Non-Small Cell Carcinoma \| Non-small cell lung cancer stage IIIA \| Bronchogenic Carcinoma ... View more	38	Carboplatin+Placlitaxel+Atezolizumab	wygydhsbrx = pchjtsgdal wdisbauisx (pklyzpgyqk, plskpeabpi - lrtzqjqbft) View more	-	22 Jul 2026
NCT04527900 (CTgov)	Phase 2	Advanced Endometrial Carcinoma	2	pelvic IMPT (Intensity Modulated Proton Therapy)+carboplatin+paclitaxel	uwwhhejmlw = bvhjkwlajm ipfulialxb (qikvelqrje, glsmhvappo - tiqbfsfubv) View more	-	08 Jul 2026
NCT05519241 (Pubmed \| Nanomedicine (Lond))	Phase 1	Non-Muscle Invasive Bladder Neoplasms	3	PLZ4-coated paclitaxel-loaded micelles (PPM)	fmdrtfzatx(ceikxofnwd) = No drug-related adverse event was observed lwmjvidtma (agcfofwehk )	Positive	03 Jul 2026
NCT04929392 (CTgov)	Phase 2	Adenocarcinoma of Esophagus \| Gastrooesophageal junction cancer \| Esophageal Squamous Cell Carcinoma ... View more	3	External Beam Radiation Therapy+Carboplatin+Paclitaxel+Pembrolizumab+Lenvatinib Mesylate	kinesvspkr = jniapvfglk ndutfxdank (optbesjazj, jgdbercngz - sxfjbhdcor) View more	-	23 Jun 2026
NCT06332092 (FID-007-003, ASCO2026)	Phase 2	Squamous Cell Carcinoma of Head and Neck	45	FID-007 75 mg/m2	gwuxnhcrzr(gtfuqjgbxs) = rqrbthbphi ggnkpxmoln (jmqcuesmnn ) View more	Positive	29 May 2026
NCT06332092 (FID-007-003, ASCO2026)	Phase 2	Squamous Cell Carcinoma of Head and Neck	45	FID-007 125 mg/m2	gwuxnhcrzr(gtfuqjgbxs) = lzlrgeporo ggnkpxmoln (jmqcuesmnn ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	squamous cell carcinoma of the anus First line	54	Q3-week carboplatin-paclitaxel	byytpznpba(nxnvngxiwp) = huxytysjhh wldyujbohh (ovamqwfjal, 15.7 - NR) View more	Positive	29 May 2026
ASCO2026	Not Applicable	squamous cell carcinoma of the anus First line	54	Standard (d1,8,15 Q28-day cycle) carboplatin-paclitaxel	byytpznpba(nxnvngxiwp) = xkecnithbn wldyujbohh (ovamqwfjal, 11.2 - NR) View more	Positive	29 May 2026
NCT04090398 (ETCTN 10302, ASCO2026)	Phase 2	Metastatic breast cancer HER2-negative	70	Radium-223 dichloride + Paclitaxel	cocmjaqhol(qjyhwpkhyu) = safmrbejen ruygeidwyi (oppcvztjma ) View more	Negative	29 May 2026
NCT04090398 (ETCTN 10302, ASCO2026)	Phase 2	Metastatic breast cancer HER2-negative	70	Paclitaxel	cocmjaqhol(qjyhwpkhyu) = ouicbqkvse ruygeidwyi (oppcvztjma ) View more	Negative	29 May 2026